Evidence map›Paper›PMID 25045611›Full record

ArticleSpringerPlus2014

Health resource utilization associated with skeletal-related events in patients with advanced breast cancer: results from a prospective, multinational observational study.

Diana Lüftner, Vito Lorusso, Ignacio Duran, Guy Hechmati, Cristina Garzon-Rodriguez, John Ashcroft, Amit Bahl, Prayashi Ghelani, Rachel Wei, Emma Thomas and 1 more

Registry-linked trialAbstract read
In one paragraph

Article in SpringerPlus, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05534321 (Prophylactic Radiotherapy of MInimally Symptomatic Spinal Disease), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05534321 phase1 / phase2recruitingnot on this mapstarted 2022, after this paper: background citation

Prophylactic Radiotherapy of MInimally Symptomatic Spinal Disease (PROMISSeD Trial)

TypeinterventionalSponsorBaptist Health South FloridaRan2022 to 2027Enrolled74ConditionsSpine MetastasesArmsProphylactic Radiotherapy, Standard of care systemic therapy
3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Ten-year experience of bone SBRT in breast cancer: analysis of predictive factors of effectiveness.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Article
  5. The impact of bone mineral density screening on incident fractures and healthcare resource utilization among postmenopausal breast cancer survivors treated with aromatase inhibitors.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2022
    Article
  6. Article
  7. Article
  8. Role of Bisphosphonates in Breast Cancer Therapy.Current treatment options in oncology · 2019
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Diana LüftnerCharité Universitätsmedizin Berlin, Berlin, Germany.
Vito LorussoNational Cancer Institute IRCCS Giovanni Paolo II, Bari, Italy ; Oncology Institute ASL, Lecce, Italy.
Ignacio DuranCentro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain.
Guy HechmatiHealth Economics, Amgen (Europe) GmbH, Zug, Switzerland.
Cristina Garzon-RodriguezInstituto Catalán d'Oncología ICO-IDIBELL, Barcelona, Spain.
John AshcroftPinderfields General Hospital, Wakefield, UK.
Amit BahlUniversity Hospitals Bristol, Bristol, UK.
Prayashi GhelaniBiostatistics, Ovatech Solutions, London, UK.
Rachel WeiBiostatistics, Amgen Inc, Thousand Oaks, CA USA.
Emma ThomasScientific Publications, Amgen (Europe) GmbH, Zug, Switzerland.
Herbert HoefelerForschungszentrum Ruhr, Witten, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with breast cancer and bone metastases often experience skeletal complications (skeletal-related events [SREs]: pathologic fracture, radiation to bone, surgery to bone or spinal cord compression). Prospective data on the health resource burden of SREs are needed for planning healthcare requirements and estimating the value of new treatments, but limited data are available. This prospective, observational study collected health resource utilization (HRU) data independently attributed to SREs by investigators. Eligible patients had bone metastases secondary to breast cancer, life expectancy ≥6 months, Eastern Cooperative Oncology Group (ECOG) performance status ≤2, and at least one SRE in the 97 days before enrollment. Data, collected retrospectively for 97 days before enrollment and prospectively for 18-21 months, included number and duration of inpatient stays, outpatient visits, emergency room visits and procedures. Altogether, 223 patients were enrolled from Germany, Italy, Spain and the UK. Of the 457 SREs, 118 (25.8%) were associated with inpatient stays. The mean duration of stay was 19.5 (standard deviation [SD] 19.2) days per SRE (based on 117 SREs). Surgery to bone and spinal cord compression were the SREs most likely to require inpatient stays (77.8% and 57.9% of SREs, respectively), while radiation to bone was the least likely (9.7%). Spinal cord compression required the longest inpatient stay per event (34.2 [SD 30.2] days) and radiation to bone the shortest (14.3 [SD 10.2] days). Overall, 342 SREs (74.8%) required an outpatient visit, with radiation to bone the most likely (85.7%), and surgery to bone the least likely (42.6%). Radiation to bone was also associated with the greatest number of outpatient visits per event (6.8 [SD 6.7] visits). All SREs were associated with substantial HRU therefore, preventing SREs in patients with breast cancer may reduce the burden imposed on healthcare systems.

Indexed as

Bone metastasesBreast cancerEuropeHealth resource utilizationSkeletal-related events

Identifiers

PMID25045611
PMCPMC4093906

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.